This expands ESTEVE’s portfolio of medications for rare and severe diseases with three products to treat Cushing’s syndrome and adrenocortical carcinoma; and drives its international growth.

ESTEVE has completed the acquisition of HRA Pharma Rare Diseases, a business specialized in rare diseases, from Perrigo Company plc.

With this acquisition, ESTEVE expands its portfolio in rare and severe diseases adding, to the current existing offer, three new medications to treat Cushing’s syndrome and adrenocortical carcinoma: Metopirone, Lysodren, and Ketoconazole HRA.

HRA Pharma Rare Diseases has been a leading company for over 15 years in rare and severe diseases, providing the best care and services to individuals living with rare diseases, and is committed to supporting healthcare professionals worldwide.

“This acquisition allows us to accelerate our international expansion, strengthening our global presence and ability to better address unmet needs, thus improving the lives of more people,” highlights Staffan Schüberg, Chief Executive Officer of ESTEVE.

With annual net revenues in 2023 of approximately 50 million euros, HRA Pharma Rare Diseases has a presence in numerous European countries and the United States with a team of 49 individuals. This agreement represents an investment of up to 275 million euros, structured with an initial fixed contribution and future variable payments tied to revenue.